myNEO organised, together with PDCline pharma, Radboud UMC, Vaximm, and ImmunXperts, a joint webinar wherein we talked about recent revelations in the neoantigen prediction and selection field.
Watch the video recording of the webinar here:
The following topics were discussed:
- Promise and challenges of neoantigen-driven immunotherapeutics (myNEO)
- New class of cancer vaccine based on an off-the-shelf Antigen Presenting Cell line (PDC*line Pharma)
- Genetic delivery of neoantigens with VXM, a robust and easy to use oral delivery platform (Vaximm)
- LncRNA-encoded microproteins - novel tumour antigens? (Radboud UMC)
- In vitro screening and validation of neoepitopes (ImmunXperts)